Both MAPKi-resistant BRAFV600E-mutated melanoma cell lines and tumour biopsies obtained from human MAPKi-resistant BRAFV600E patients express high levels of ZEB1 but low levels of ZEB2 and MITF. This evidence concerns the gene ZEB2 and neoplasm.